Lisa Strovink, MBA, has spent her career working to bring new therapies to market, focusing on early-stage health care technology. She founded and is currently a Managing Partner at AllerFund, the first and only venture fund dedicated to driving social impact for those with food allergies. Prior to Allerfund, Lisa was the Chief Strategy Officer at the New York Stem Cell Foundation Research Institute. There, she oversaw partnerships and strategic operations of the research institute and started and ran their cell therapy programs. These included an early research program on T-Regulatory cells, one of the cell types involved in allergy and autoimmunity. Lisa previously held a range of strategic and operational roles at Johnson & Johnson, including the Director of Strategic Planning for the Medical Devices and Diagnostics group, Director of U.S. Marketing for Cordis Endovascular, Director of the Carotid Stent Program, and as a Director in a disease-focused fund which invested in pre-clinical and clinical stage products across the pharmaceutical, device, diagnostics and consumer sectors. Lisa began her career as a management consultant with McKinsey & Company, where she advised pharmaceutical and medical device companies and health care providers on strategy, growth, and innovation, portfolio management, product launch, and business development, specializing in early-stage technology and market assessment.
Lisa holds a BA in neurobiology from the University of Pennsylvania (summa cum laude) and an MBA from Harvard Business School. She currently serves on the Memorial Sloan Kettering Technology Development Fund External Review Committee. Lisa is a mother of two boys with food allergies.